Application of garcinia 3 ', 7-di-O-glucoside in preparation of anti-leukemia drugs

By using gazepamin-3',7-di-O-glucoside to inhibit the proliferation of leukemia cells and induce their apoptosis, the problem of the existing leukemia treatment methods is solved, and a new The treatment options improve cure rates and reduce side effects, with broad clinical application prospects.

CN118903167APending Publication Date: 2024-11-08THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410851422.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-28
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing leukemia treatment methods such as chemotherapy and radiotherapy are often accompanied by severe side effects and have limited therapeutic effects. It is urgent to develop new anti-leukemia drugs that are more effective and have fewer side effects.

Method used

Using Garcin-3',7-di-O-glucoside as an antileukemia drug provides a new therapeutic option by inhibiting the proliferation of leukemia cells and promoting their apoptosis.

Benefits of technology

Garcincin-3',7-di-O-glucoside can effectively inhibit the proliferation of leukemia cells and significantly promote their apoptosis, providing a new therapeutic option, improving cure rates and improving long-term survival of patients Quality, and because it comes from natural plants, the side effects are small, and it has broad clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903167A_ABST
    Figure CN118903167A_ABST
Patent Text Reader

Abstract

The invention discloses an application of gambogic actin-3 ', 7-di-O-glucoside in preparation of an anti-leukemia drug, and belongs to the technical field of drug screening. The invention finds that the luteinim-3 ', 7-di-O-glucoside can effectively inhibit the proliferation of leukemia cells and obviously promote the apoptosis of the leukemia cells, thereby providing a new treatment choice for leukemia patients, further optimizing the treatment scheme of the leukemia patients, increasing the cure rate and improving the long-term life quality of the patients. In addition, the garcinidin-3 ', 7-di-O-glucoside is derived from natural plants, so that the side effect is relatively small, and the garcinidin-3', 7-di-O-glucoside has a wide clinical application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug screening, and specifically relates to the application of luteolin-3',7-di-O-glucoside in the preparation of anti-leukemia drugs. Background Art

[0002] Leukemia is a type of malignant tumor of the hematopoietic system, characterized by the presence of abnormally proliferating immature white blood cells in the bone marrow and other hematopoietic tissues. Currently, the treatments for leukemia mainly include chemotherapy, radiotherapy, and hematopoietic stem cell transplantation, but these methods are often accompanied by serious side effects and have limited therapeutic effects. Therefore, there is an urgent need to develop new anti-leukemia drugs that are more effective and have fewer side effects.

[0003] Luteolin-3',7-di-O-glucoside is a flavonoid compound and a derivative of luteolin. Luteolin is widely found in many plants, including Rutaceae and Asteraceae, and has a variety of biological activities, such as antioxidant, anti-inflammatory, antiviral and anti-tumor. Its structural formula is as follows:

[0004]

[0005] Studies have shown that luteolin can inhibit the growth and proliferation of tumor cells through multiple mechanisms, including inducing cell apoptosis, blocking the cell cycle and inhibiting tumor angiogenesis.

[0006] As a derivative of luteolin, luteolin-3',7-di-O-glucoside has similar biological activity to luteolin, but there is currently no research on the anti-tumor activity of luteolin-3',7-di-O-glucoside. Summary of the invention

[0007] In view of the above-mentioned prior art, the present invention provides a use of luteolin-3',7-di-O-glucoside in the preparation of anti-leukemia drugs, in order to provide new ideas and methods for the treatment of leukemia.

[0008] In order to achieve the above-mentioned object, the technical solution adopted by the present invention is to provide a use of luteolin-3',7-di-O-glucoside in the preparation of anti-leukemia drugs.

[0009] Based on the above technical solution, the present invention can also be improved as follows.

[0010] Furthermore, the drug is a drug that inhibits the activity of leukemia cells HL60 and / or Thp1 cells.

[0011] Furthermore, the effective concentration of the drug is 20 to 100 μM.

[0012] Furthermore, pharmaceutically acceptable salts are also included.

[0013] The beneficial effects of the present invention are as follows: the present invention finds that luteolin-3',7-di-O-glucoside can effectively inhibit the proliferation of leukemia cells and significantly promote their apoptosis, which provides a new treatment option for leukemia patients, can further optimize the treatment plan for leukemia patients, improve the cure rate, and improve the long-term survival quality of patients. Luteolin-3',7-di-O-glucoside is derived from natural plants, has less side effects, and has broad clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 This is a graph showing the changes in cell viability of leukemia cell HL60 treated with different concentrations of luteolin-3',7-di-O-glucoside;

[0015] Figure 2 The results of flow cytometry apoptosis detection of HL60 cells after 24 hours of treatment with luteolin-3',7-di-O-glucoside;

[0016] Figure 3 This is a graph showing the changes in cell viability of leukemia cell Thp1 treated with different concentrations of luteolin-3',7-di-O-glucoside;

[0017] Figure 4 The results of flow cytometry apoptosis detection of Thp1 cells after treatment with luteolin-3',7-di-O-glucoside for 24 hours. DETAILED DESCRIPTION

[0018] The reagents used in the present invention are as follows:

[0019] Reagents company nation Fetal bovine serum VivaCell China RPMI 1640 Gibco China penicillin Gibco China Streptomycin Gibco China CCK-8 Kit APExBIO USA 1000μL, 200μL, 10μL Tips Axygen USA 1.5mL EP tube Axygen USA Apoptosis Kit BD USA Leukemia cell line HL60 Shanghai Yingwan Biotechnology Co., Ltd. China Thp1 cells Shanghai Yingwan Biotechnology Co., Ltd. China

[0020] The preparation method of the culture medium used in the present invention is:

[0021] For every 100 mL of cell culture medium: take 89 mL of RPMI 1640, add 10 mL of fetal bovine serum, then add 1 mL of double antibody, mix well, and store at 4°C.

[0022] The specific implementation modes of the present invention are described in detail below with reference to the embodiments.

[0023] Example 1: Inhibitory effect of luteolin-3',7-di-O-glucoside on proliferation of leukemia cells HL60

[0024] (1) taking leukemia HL60 cells, inoculating them into culture medium, and culturing them to the logarithmic phase under the conditions of 37° C., 5% CO 2 , and 90% humidity;

[0025] (2) HL60 cells in logarithmic phase growth were taken and inoculated into a 96-well plate containing culture medium at a rate of 20,000 cells / well. Luteolin-3',7-di-O-glucoside and an equal volume of DMSO (dimethyl sulfoxide, the final concentration of which was controlled below 1‰ (v / v)) were added to the experimental groups, respectively. 10 μL of serum-free RPMI1640 culture medium was added to the negative control group, and a blank zero adjustment group was set up, with 3 replicate wells in each group. The 96-well plate was then placed in a constant temperature cell culture incubator and cultured at 37°C, 5% CO2, and 90% humidity for 24 hours. Subsequently, 10 μL of CCK8 solution was added to each well, and the cells were incubated at 37°C, 5% CO2 for 4 hours. The absorbance OD value of each well was detected at 450 nm using an enzyme reader. The average OD value of each group was calculated, and the cell proliferation inhibition rate was calculated according to the following formula:

[0026] Proliferation inhibition rate (%) = (OD value of control group - OD value of experimental group) / (OD value of control group - OD value of blank group) × 100%

[0027] Fitting the cell activity curve, the results are as follows Figure 1 As shown in the figure, it can be seen that luteolin-3',7-di-O-glucoside can significantly inhibit the proliferation of HL60 cells.

[0028] Example 2: Effect of Luteolin-3',7-di-O-glucoside on the Apoptosis Induction of Leukemia Cells HL60

[0029] (1) Inoculate 1 mL of culture medium in a 6-well plate at a density of (5-10)×10 5 HL60 cells growing in logarithmic phase at 100 μM / mL were added with luteolin-3',7-di-O-glucoside to make the final concentrations 20, 40, and 60 μM, respectively; the cells were cultured at 37°C, 5% CO2, and 90% humidity for 24 hours, and the cells were collected after 24 hours;

[0030] (2) Follow the steps of the Annexin V / PI cell apoptosis kit, wash the cells twice with PBS, then resuspend the cells in 400 μL of 1× Binding buffer, add 5 μL of Annexin-VFITC and 5 μL of propidium iodide, and detect the cell apoptosis rate by flow cytometry. The results are as follows: Figure 2 As shown in the figure, it can be seen that luteolin-3',7-di-O-glucoside can significantly induce apoptosis of HL60 cells, and the apoptosis rate increases significantly with the increase of luteolin-3',7-di-O-glucoside concentration, and the highest apoptosis rate reaches 21.32%.

[0031] Example 3: Inhibitory effect of luteolin-3',7-di-O-glucoside on proliferation of leukemia cells Thp1

[0032] (1) Thp1 cells were taken and inoculated into culture medium, and cultured to the logarithmic phase under the conditions of 37°C, 5% CO2, and 90% humidity;

[0033] (2) Take Thp1 cells in logarithmic phase and inoculate 20,000 cells / well in a 96-well plate containing culture medium. Luteolin-3',7-di-O-glucoside and an equal volume of DMSO (dimethyl sulfoxide, the final concentration of which is controlled below 1‰ (v / v)) are added to the experimental groups, respectively. 10 μL of serum-free RPMI1640 culture medium is added to the negative control group, and a blank zero adjustment group is set up, with 3 replicates for each group. Then the 96-well plate is placed in a constant temperature cell culture incubator and cultured at 37°C, 5% CO2, and 90% humidity for 24 hours. Subsequently, 10 μL of CCK8 solution is added to each well, and the cells are incubated at 37°C, 5% CO2 for 4 hours. The absorbance OD value of each well is detected at 450 nm using an enzyme reader. The average OD value of each group is calculated, and the cell proliferation inhibition rate is calculated according to the following formula:

[0034] Proliferation inhibition rate (%) = (OD value of control group - OD value of experimental group) / (OD value of control group - OD value of blank group) × 100%

[0035] Fitting cell activity curves, such as Figure 3 As shown in the figure, it can be seen that luteolin-3',7-di-O-glucoside can significantly inhibit the proliferation of Thp1 cells.

[0036] Example 4: Effect of Luteolin-3',7-di-O-glucoside on the Apoptosis Induction of Leukemia Cells Thp1

[0037] (1) Inoculate 1 mL of the solution in a 6-well plate at a density of (5-10)×10 5 Thp1 cells growing in logarithmic phase at 100 μM / mL were added with luteolin-3',7-di-O-glucoside to make the final concentrations 20, 40, and 60 μM, respectively; the cells were cultured at 37°C, 5% CO2, and 90% humidity for 24 hours, and the cells were collected after 24 hours;

[0038] (2) Follow the steps of the Annexin V / PI cell apoptosis kit, wash the cells twice with PBS, then resuspend the cells in 400 μL of 1× Binding buffer, add 5 μL of Annexin-VFITC and 5 μL of propidium iodide, and detect the cell apoptosis rate by flow cytometry. The results are as follows: Figure 4As shown in the figure, it can be seen that luteolin-3',7-di-O-glucoside can significantly induce apoptosis of Thp1 cells, and the apoptosis rate increases significantly with the increase of luteolin-3',7-di-O-glucoside concentration, and the highest apoptosis rate reaches 85.77%.

[0039] Although the specific implementation of the present invention is described in detail in conjunction with the embodiments, it should not be understood as limiting the scope of protection of this patent. Within the scope described in the claims, various modifications and variations that can be made by those skilled in the art without creative work still fall within the scope of protection of this patent.

Claims

1. Application of luteolin-3',7-di-O-glucoside in the preparation of anti-leukemia drugs.

2. The use according to claim 1, characterized in that: The drug is a drug for inhibiting the activity of leukemia cells HL60 and / or Thp1 cells.

3. The use according to claim 2, characterized in that: The effective concentration of the drug is 20-100 μM.

4. The use according to claim 3, characterized in that: Pharmaceutically acceptable salts are also included.